![](https://endpts.com/wp-content/uploads/2024/01/Emil-Kakkis-Ultragenyx.jpg)
Emil Kakkis, Ultragenyx CEO
Ultragenyx nears $50M Series A for its Alzheimer's gene therapy spinout: #JPM24
SAN FRANCISCO — Ultragenyx, the commercial-stage California biotech working on ultra-rare diseases, is finishing up a $50 million Series A fundraise for its Alzheimer’s gene …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.